IE54330B1 - Derivatives of 2-phenyl-morpholine and therapeutic compositions - Google Patents
Derivatives of 2-phenyl-morpholine and therapeutic compositionsInfo
- Publication number
- IE54330B1 IE54330B1 IE2840/82A IE284082A IE54330B1 IE 54330 B1 IE54330 B1 IE 54330B1 IE 2840/82 A IE2840/82 A IE 2840/82A IE 284082 A IE284082 A IE 284082A IE 54330 B1 IE54330 B1 IE 54330B1
- Authority
- IE
- Ireland
- Prior art keywords
- crl
- morpholine
- dose
- phenyl
- hour
- Prior art date
Links
- ZLNGFYDJXZZFJP-UHFFFAOYSA-N 2-phenylmorpholine Chemical class C1NCCOC1C1=CC=CC=C1 ZLNGFYDJXZZFJP-UHFFFAOYSA-N 0.000 title claims abstract description 10
- 239000000203 mixture Substances 0.000 title claims description 15
- 230000001225 therapeutic effect Effects 0.000 title claims description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 239000002253 acid Substances 0.000 claims abstract description 14
- RLMOVFUYZBCTKX-UHFFFAOYSA-N 4-ethyl-2-phenylmorpholine Chemical compound C1N(CC)CCOC1C1=CC=CC=C1 RLMOVFUYZBCTKX-UHFFFAOYSA-N 0.000 claims abstract description 10
- UBQMBBSAKGENED-UHFFFAOYSA-N 4-methyl-2-(2-methylphenyl)morpholine Chemical compound C1N(C)CCOC1C1=CC=CC=C1C UBQMBBSAKGENED-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract 1
- 230000002631 hypothermal effect Effects 0.000 description 20
- 206010021113 Hypothermia Diseases 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 16
- 206010039897 Sedation Diseases 0.000 description 16
- 230000004899 motility Effects 0.000 description 16
- 230000036280 sedation Effects 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 208000006550 Mydriasis Diseases 0.000 description 11
- 230000009471 action Effects 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 206010021143 Hypoxia Diseases 0.000 description 8
- 229960004046 apomorphine Drugs 0.000 description 8
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 8
- 206010042008 Stereotypy Diseases 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 238000007912 intraperitoneal administration Methods 0.000 description 7
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 206010002660 Anoxia Diseases 0.000 description 6
- 241000976983 Anoxia Species 0.000 description 6
- RSDOPYMFZBJHRL-UHFFFAOYSA-N Oxotremorine Chemical compound O=C1CCCN1CC#CCN1CCCC1 RSDOPYMFZBJHRL-UHFFFAOYSA-N 0.000 description 6
- 230000007953 anoxia Effects 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 6
- 239000007928 intraperitoneal injection Substances 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000002269 spontaneous effect Effects 0.000 description 6
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 5
- 206010010904 Convulsion Diseases 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 206010035039 Piloerection Diseases 0.000 description 5
- BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 5
- 229940025084 amphetamine Drugs 0.000 description 5
- BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 5
- 230000036461 convulsion Effects 0.000 description 5
- 230000005371 pilomotor reflex Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 229960000317 yohimbine Drugs 0.000 description 5
- BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 5
- AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 5
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 4
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 4
- 206010039424 Salivary hypersecretion Diseases 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical group CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 230000001242 postsynaptic effect Effects 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 4
- 229960003147 reserpine Drugs 0.000 description 4
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 4
- 208000026451 salivation Diseases 0.000 description 4
- 235000011121 sodium hydroxide Nutrition 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 229960002319 barbital Drugs 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000001713 cholinergic effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 239000000842 neuromuscular blocking agent Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 230000003518 presynaptic effect Effects 0.000 description 3
- 239000012429 reaction media Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 206010020843 Hyperthermia Diseases 0.000 description 2
- 206010023644 Lacrimation increased Diseases 0.000 description 2
- OPKOKAMJFNKNAS-UHFFFAOYSA-N N-methylethanolamine Chemical compound CNCCO OPKOKAMJFNKNAS-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 230000016571 aggressive behavior Effects 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 230000036031 hyperthermia Effects 0.000 description 2
- 230000004317 lacrimation Effects 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 231100001160 nonlethal Toxicity 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
- OZLPUNFFCJDMJD-UHFFFAOYSA-N 2-[2,3-bis[2-(triethylammonio)ethoxy]phenoxy]ethyl-triethylammonium Chemical compound CC[N+](CC)(CC)CCOC1=CC=CC(OCC[N+](CC)(CC)CC)=C1OCC[N+](CC)(CC)CC OZLPUNFFCJDMJD-UHFFFAOYSA-N 0.000 description 1
- WFFXVNGBCLDNRF-UHFFFAOYSA-N 2-methyl-2-(2-methylphenyl)morpholine Chemical compound CC1=CC=CC=C1C1(C)OCCNC1 WFFXVNGBCLDNRF-UHFFFAOYSA-N 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 206010015995 Eyelid ptosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- AWMVMTVKBNGEAK-UHFFFAOYSA-N Styrene oxide Chemical compound C1OC1C1=CC=CC=C1 AWMVMTVKBNGEAK-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000002539 anti-aggressive effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 229940116592 central nervous system diagnostic radiopharmaceuticals Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 1
- XTLNYNMNUCLWEZ-UHFFFAOYSA-N ethanol;propan-2-one Chemical compound CCO.CC(C)=O XTLNYNMNUCLWEZ-UHFFFAOYSA-N 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229960003054 gallamine Drugs 0.000 description 1
- REEUVFCVXKWOFE-UHFFFAOYSA-K gallamine triethiodide Chemical compound [I-].[I-].[I-].CC[N+](CC)(CC)CCOC1=CC=CC(OCC[N+](CC)(CC)CC)=C1OCC[N+](CC)(CC)CC REEUVFCVXKWOFE-UHFFFAOYSA-K 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000035873 hypermotility Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 206010043089 tachypnoea Diseases 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8122507A FR2517305B1 (fr) | 1981-12-01 | 1981-12-01 | Nouveaux derives de 2-phenyl-morpholine et leur utilisation en therapeutique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE822840L IE822840L (en) | 1983-06-01 |
| IE54330B1 true IE54330B1 (en) | 1989-08-30 |
Family
ID=9264557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE2840/82A IE54330B1 (en) | 1981-12-01 | 1982-11-29 | Derivatives of 2-phenyl-morpholine and therapeutic compositions |
Country Status (12)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2553410B1 (fr) * | 1983-10-14 | 1986-05-16 | Lafon Labor | Nouveaux derives de 2-tolyl-morpholine utiles en therapeutique |
| FR2564462B1 (fr) * | 1984-05-16 | 1986-11-21 | Lafon Labor | Derives de la 2-phenyl-morpholine utiles en therapeutique |
| GB9108629D0 (en) * | 1991-04-23 | 1991-06-12 | Wellcome Found | Heterocyclic pharmaceutical compounds,preparation and use |
| AU3364493A (en) * | 1992-01-28 | 1993-09-01 | Smithkline Beecham Plc | Compounds as calcium channel antagonists |
| CA2422055A1 (en) | 2000-09-11 | 2002-03-21 | Sepracor, Inc. | Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission) |
| US7294637B2 (en) | 2000-09-11 | 2007-11-13 | Sepracor, Inc. | Method of treating addiction or dependence using a ligand for a monamine receptor or transporter |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2835669A (en) * | 1958-05-20 | Process for the production of substi- | ||
| GB851311A (en) * | 1958-04-02 | 1960-10-12 | Geigy Ag J R | Morpholine compounds and their production |
| FR1535615A (fr) * | 1967-06-26 | 1968-08-09 | Ct Europ De Rech S Mauvernay | Procédé pour l'obtention de tétrahydro-1, 4-oxazines substituées en 2, 4 et en 2, 2, 4 |
| FR2471378A1 (fr) * | 1979-12-14 | 1981-06-19 | Lafon Labor | Derives de 2-phenyl-morpholine, leur procede de preparation et leur application en therapeutique |
-
1981
- 1981-12-01 FR FR8122507A patent/FR2517305B1/fr not_active Expired
-
1982
- 1982-11-17 GR GR69842A patent/GR77037B/el unknown
- 1982-11-25 AT AT82402147T patent/ATE18043T1/de not_active IP Right Cessation
- 1982-11-25 EP EP82402147A patent/EP0080940B1/fr not_active Expired
- 1982-11-25 DE DE8282402147T patent/DE3269247D1/de not_active Expired
- 1982-11-29 ZA ZA828758A patent/ZA828758B/xx unknown
- 1982-11-29 IE IE2840/82A patent/IE54330B1/en unknown
- 1982-11-29 ES ES517779A patent/ES8308317A1/es not_active Expired
- 1982-11-30 AU AU91004/82A patent/AU9100482A/en not_active Abandoned
- 1982-11-30 CA CA000416708A patent/CA1189861A/en not_active Expired
- 1982-11-30 DK DK531582A patent/DK531582A/da not_active Application Discontinuation
- 1982-12-01 JP JP57211199A patent/JPS58103377A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| ES517779A0 (es) | 1983-08-16 |
| FR2517305B1 (fr) | 1985-10-25 |
| IE822840L (en) | 1983-06-01 |
| ES8308317A1 (es) | 1983-08-16 |
| CA1189861A (en) | 1985-07-02 |
| EP0080940A2 (fr) | 1983-06-08 |
| JPH0254831B2 (enrdf_load_stackoverflow) | 1990-11-22 |
| AU9100482A (en) | 1983-06-09 |
| DK531582A (da) | 1983-06-02 |
| EP0080940B1 (fr) | 1986-02-19 |
| DE3269247D1 (en) | 1986-03-27 |
| EP0080940A3 (en) | 1983-07-06 |
| GR77037B (enrdf_load_stackoverflow) | 1984-09-04 |
| FR2517305A1 (fr) | 1983-06-03 |
| ATE18043T1 (de) | 1986-03-15 |
| JPS58103377A (ja) | 1983-06-20 |
| ZA828758B (en) | 1983-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4927855A (en) | Levorotatory isomer of benzhydrylsulfinyl derivatives | |
| CA1199916A (en) | Benzhydrylsulfinylacetamide derivatives | |
| US4225617A (en) | Acetohydroxamic acids | |
| US4177290A (en) | Acetamide derivatives | |
| US4146647A (en) | Substituted phenyl-amidines | |
| CS200195B2 (cs) | Zapojení ventilu pro regulaci brzdného tlaku ve vzduchotlakových brzdových soustavách | |
| US3205136A (en) | Antidepressant phenyloxyalkylamines | |
| IE54330B1 (en) | Derivatives of 2-phenyl-morpholine and therapeutic compositions | |
| FR2576898A1 (fr) | Derives de 3-phenyl-tetrahydropyridine, procede de preparation et utilisation en therapeutique | |
| FR2569184A1 (fr) | Derives de 1-(aminophenyl) therapeutique et leur procede de preparation | |
| US4714699A (en) | 2-tolylmorpholine derivatives and pharmaceutical compositions | |
| US4835315A (en) | Fluorophenacyl-amine derivatives and application thereof in therapeutics | |
| US4576944A (en) | 4-Ethyl-2-hydroxy-3-methyl-2-phenylmorpholine, compositions and use | |
| US4201725A (en) | Secondary amines | |
| US4912110A (en) | Antidepressive substituted phenylpiperazine compounds | |
| US4407822A (en) | Benzamido-alkyl-hydroxamic acid derivatives | |
| US3855249A (en) | 4-phenoxy-3-hydroxy-butyramidine derivatives | |
| US4026925A (en) | Active derivatives of methylamine, therapeutic compositions containing the same and processes for preparing the said derivatives and compositions | |
| US4816489A (en) | 1-(aminophenyl)-2-aminoethanone derivatives | |
| FR2553411A1 (fr) | Derives de 2-halogenophenyl-morpholine, procede de preparation et utilisation en therapeutique | |
| US4271161A (en) | Indane-acetic acid aminoesters, their preparation and their use in therapy | |
| US4690950A (en) | 1-[N-(α-amino-α-methylacetyl)aminophenyl]-2-aminopropanone derivatives | |
| US4057644A (en) | Active derivatives of methylamine in therapeutic compositions and methods of use | |
| US3711538A (en) | Delta 2,alpha-adamantaneacetanilide derivatives and related compounds | |
| US4545996A (en) | N-(4-Acetylaminophenacyl)amine derivatives useful as pharmaceuticals |